GLP-1 and hormone balance: what TikTok gets wrong

What did @zacharyklassen actually say?

The creator claims that "Ozempic face" is caused by muscle loss specifically around the eyes and cheeks, not fat loss. He argues that GLP-1 medications cause muscle wasting throughout the body, including facial muscles, and that this muscle loss is what makes people look older. He wraps it up with the analogy that prescribing Ozempic is like "trying to fix your engine by turning down your radio."

This is a specific mechanistic claim: that facial aging on semaglutide is driven by muscle atrophy in the orbital and cheek regions, not subcutaneous fat depletion. That distinction matters, because the intervention you'd recommend differs depending on which tissue is actually responsible. Let's look at what the evidence actually says.

Does the science back this up?

Partially, but the framing is wrong in important ways. GLP-1 agonists do cause lean mass loss alongside fat loss, but the face claim overstates a specific mechanism that hasn't been studied directly.

The lean mass loss concern is real. A 2021 trial by Wilding et al. in the New England Journal of Medicine found that semaglutide produced approximately 15% total body weight loss, with roughly one-third of that coming from lean mass. This is consistent with what happens during most caloric-restriction-driven weight loss, drug-assisted or not. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed similar patterns with tirzepatide. Lean mass loss during rapid weight loss is a legitimate clinical concern.

But the creator's specific claim, that muscle loss around the orbital bones and cheeks is the primary driver of "Ozempic face," is not supported by imaging studies. Dermatology literature points to subcutaneous fat compartment deflation as the main culprit. Facial fat pads, not muscles, are what give the midface its volume. When those fat compartments shrink rapidly, the overlying skin loses support. Saying it's muscle loss in the face is a misreading of the anatomy.

What did they get wrong (or right)?

They got the lean mass concern right but the facial anatomy wrong, and that's not a small error.

Facial muscles, the orbicularis oculi and zygomaticus for example, are not primary structural supports for facial volume. That role belongs to fat compartments: the malar fat pad, the nasolabial fat, the buccal fat pad. When patients lose weight rapidly, these compartments deflate. Plastic surgeons and dermatologists who treat post-GLP-1 facial changes use fillers and fat transfer, not muscle-building protocols, because they're replacing lost volume in fat tissue, not muscle.

The creator also implies that doctors recommending Ozempic are ignoring muscle preservation entirely. That's unfair. Most evidence-based prescribers pair GLP-1 therapy with resistance training guidance and adequate protein intake specifically to protect lean mass. Clinical guidelines from the American Diabetes Association and obesity medicine societies address this directly.

Where he deserves credit: raising the lean mass question at all is legitimate. Muscle loss during GLP-1-assisted weight loss is underappreciated, and the conversation about concurrent resistance training is worth having. The problem is he built a specific anatomical story around it that doesn't hold up.

What should you actually know?

If you're on a GLP-1 medication, lean mass preservation is a real consideration, but the solution isn't avoiding the medication. It's optimizing around it.

A 2023 review by Biancalana et al. in Nutrients examined protein intake strategies during GLP-1-assisted weight loss and found that higher protein consumption combined with resistance exercise significantly attenuated lean mass loss. This is standard practice in medically supervised programs. The face changes people notice are primarily fat-related, and they're not universal. Rapid weight loss of any kind, whether from GLP-1 medications, bariatric surgery, or aggressive dieting, can cause facial volume loss. The medication isn't uniquely to blame for the mechanism.

If facial changes are a concern, the conversation to have is with your prescriber about rate of weight loss, protein targets, and resistance training. Not whether to take the medication at all. The creator's framing, that your doctor recommending Ozempic is like "turning down your radio," dramatically oversimplifies a risk-benefit calculation that involves metabolic disease, cardiovascular outcomes, and quality of life.

Is there anything worth taking from this video?

Yes, one thing. The broader point that muscle mass matters for both metabolic health and physical appearance is well-supported. Sarcopenia does affect skin laxity over time, and resistance training has documented benefits for body composition during weight loss interventions. If this video motivates someone to ask their prescriber about muscle preservation strategies, that's not a bad outcome. The specific anatomy lesson, however, should be disregarded.